Generic Moxatag Availability

Moxatag is a brand name of amoxicillin, approved by the FDA in the following formulation(s):

MOXATAG (amoxicillin - tablet, extended release;oral)

  • Manufacturer: PRAGMA PHARMS LLC
    Approval date: January 23, 2008
    Strength(s): 775MG [RLD]

Has a generic version of Moxatag been approved?

No. There is currently no therapeutically equivalent version of Moxatag available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Moxatag. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Antibiotic product, use and formulation thereof
    Patent 6,544,555
    Issued: April 8, 2003
    Inventor(s): Edward M.; Rudnic & James D.; Isbister & Donald J.; Treacy, Jr. & Sandra E.; Wassink
    Assignee(s): Advancis Pharmaceutical Corp.
    An antibiotic product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
    Patent expiration dates:
    • October 13, 2020
      ✓ 
      Patent use: METHOD OF TREATING TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES IN A ONCE-A-DAY AMOXICILLIN PRODUCT
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Antibiotic product, use and formulation thereof
    Patent 6,669,948
    Issued: December 30, 2003
    Inventor(s): Edward M.; Rudnic & James D.; Isbister & Donald J.; Treacy, Jr. & Sandra E.; Wassink
    Assignee(s): Advancis Pharmaceutical Corp.
    An antibiotic product, in particular a betalactam such as cephalosporin (in particular cefuroxime and/or cefpodoxime) or a penicillin (in particular axmoxicillin or dicloxacillin) is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
    Patent expiration dates:
    • October 13, 2020
      ✓ 
      Patent use: METHOD OF TREATING TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES IN A ONCE-A-DAY AMOXICILLIN PRODUCT
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Antibiotic product, use and formulation thereof
    Patent 6,723,341
    Issued: April 20, 2004
    Inventor(s): Edward M.; Rudnic & James D.; Isbister & Donald J.; Treacy, Jr. & Sandra E.; Wassink
    Assignee(s): Advancis Pharmaceutical Corp.
    An antibiotic product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
    Patent expiration dates:
    • October 13, 2020
      ✓ 
      Patent use: METHOD OF TREATING TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES IN A ONCE-A-DAY AMOXICILLIN PRODUCT
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Pharmaceutical compositions and methods for improved bacterial eradication
    Patent 8,299,052
    Issued: October 30, 2012
    Inventor(s): Flanner; Henry H. & Guttendorf; Robert & Treacy; Donald & Clausen; Susan P. & Burnside; Beth A.
    Assignee(s): Shionogi Inc.
    A process for treating a bacterial infection with an antibiotic, comprising: administering to a patient with a bacterial infection a product that includes a modified release dosage form containing an antibiotic, said product being administered once-a-day in a dosage and for a number of days that provides a Total T>MIC sufficient to achieve at least the minimum amount of bacterial eradication for treatment of said bacterial infection.
    Patent expiration dates:
    • May 7, 2027
      ✓ 
      Patent use: USE OF ONCE-A-DAY AMOXICILLIN PRODUCT TO TREAT TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES
  • Compositions and methods for improved efficacy of penicillin-type antibiotics
    Patent 8,357,394
    Issued: January 22, 2013
    Assignee(s): Shionogi Inc.
    Disclosed are once-a-day penicillin-type antibiotic products comprising at least one modified release dosage form comprising penicillin-type antibiotics and pharmaceutically acceptable carriers, which compositions provide T>MIC90 in the serum for at least 5 hours (preferably for at least five consecutive hours), within a 24-hour dosing interval, for a given bacterial pathogen's MIC90, while providing a total dosage of the penicillin-type antibiotic for a 24-hour dosing interval.
    Patent expiration dates:
    • December 8, 2026
      ✓ 
      Drug product

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web5)